NCT01086423View on ClinicalTrials.gov

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

985

Participants

Timeline

Start Date

March 1, 2010

Primary Completion Date

November 19, 2010

Study Completion Date

November 19, 2010

Conditions
TetanusPoliomyelitisAcellular PertussisDiphtheriaHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

Infanrix-IPV/Hib™

Intramuscular, three doses

BIOLOGICAL

Infanrix Hib™

Intramuscular, three doses

BIOLOGICAL

Poliorix™

Intramuscular, three doses

Trial Locations (2)

543002

GSK Investigational Site, Wuzhou

543100

GSK Investigational Site, Wuzhou

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01086423 - Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine | Biotech Hunter | Biotech Hunter